RARE
Ultragenyx Pharmaceutical Inc.
A biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases, many of which had no approved therapy before. Its marketed medicines include CRYSVITA for a bone disorder called X-linked hypophosphatemia and MEPSEVII for a lysosomal storage disease. Founded in 2010 by pediatric geneticist Emil Kakkis, the company's name blends "ultra" (for ultra-rare diseases) with "genyx" (for genetics), and it trades on the stock market under the ticker symbol RARE.
CUSIP: 90400D108HealthcareUS1 holder
Total Value
$4.44M
Total Shares
64.0K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
